BioMarin Q1 2026 EPS Beats, Stock -1.5%

BioMarin reported Q1 2026 EPS of $0.76 versus $0.74 forecast and revenue $766 million versus $755.94 million expected.
Despite beating forecasts, after‑hours stock fell 1.52% to $53.24, trading near its 52‑week low of $50.76.
Updated full‑year 2026 guidance projects revenue $3.825‑$3.925 billion (≈20% YoY) and non‑GAAP diluted EPS $4.85‑$5.05.
Amicus acquisition expected to be dilutive in 2026 but accretive to EPS from 2027 onward, adding Galafold, Pombiliti and Opfolda.